Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 3, 2011, Pages 253-264

  Wang, Meng ^a   Medeiros, Bruno C ^b   Erba, Harry P ^c   Deangelo, Daniel J ^d   Giles, Francis J ^e   Swords, Ronan T ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Department of Hematology/Oncology ^*  (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^f University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Acute myeloid leukemia; MLN4924; Neddylation; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; AZACITIDINE; BORTEZOMIB; CULLIN; CYTARABINE; DAUNORUBICIN; MLN 4924; NEURAL PRECURSOR CELL EXPRESSED DEVELOPMENTALLY DOWNREGULATED 8 PROTEIN; ONCOPROTEIN; PROTEIN INHIBITOR; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATELECTASIS; BONE MARROW SUPPRESSION; CANCER THERAPY; CLINICAL TRIAL (TOPIC); CONSTIPATION; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG FATALITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LIVER FUNCTION; LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MUSCLE CRAMP; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN NEDDYLATION; REVIEW; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINS;

EID: 79951663751     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.550877     Document Type: Review

References (68)

1. Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145(12):913-23 (Pubitemid 351639967)
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96(10):3343-56
3. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004 (Pubitemid 36302244)
4. Lydon NB Druker BJ. Lessons learned from the development of imatinib. Leuk Res 2004;28(Suppl 1):S29-38 (Pubitemid 38251496)
5. Rabut G, Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008;9(10):969-76
6. Xirodimas DP. Novel substrates and functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans 2008;36(Pt 5):802-6
7. Xirodimas DP, Saville MK, Bourdon JC, et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004;118(1):83-97 (Pubitemid 38902816)
8. Xirodimas DP, Sundqvist A, Nakamura A, et al. Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep 2008;9(3):280-6 (Pubitemid 351330994)
9. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun 1992;185(3):1155-61
10. Yen HC, Elledge SJ. Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science 2008;322(5903):923-9
11. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37(1):102-11
12. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458(7239):732-6
13. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15(12):3912-16.. This is the first description of the chemical structure of MLN4924. The paper evaluates the activity of MLN4924 in enzyme- and cell-based assays, which demonstrate drug selectivity for its target. DNA damage and cell cycle perturbation were proposed as the principal mechanisms of action.
14. Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115(18):3796-800.
15. Kane RC, Bross PF, Farrell AT, et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8(6):508-13 (Pubitemid 37467365)
16. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98 (Pubitemid 41007864)
17. Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515-23
18. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J Biol Chem 1999;274(17):12036-42
19. Osaka F, Saeki M, Katayama S, et al. Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast. EMBO J 2000;19(13):3475-84 (Pubitemid 30428225)
20. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6(1):9-20 (Pubitemid 40064895)
21. Podust VN, Brownell JE, Glaysheva TB, et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 2000;97(9):4579-84 (Pubitemid 30238600)
22. Read MA, Brownell JE, Glaysheva TB, et al. Nedd8 modification of cul-1 activates SCF(beta(TrCP))- dependent ubiquitination of IkappaBalpha. Mol Cell Biol 2000;20(7):2326-33 (Pubitemid 30152040)
23. Russell RC, Ohh M. NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL. EMBO Rep 2008;9(5):486-91 (Pubitemid 351627288)
24. Schulman BA, Harper JW. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009;10(5):319-31
25. Shen LN, Liu H, Dong C, et al. Structural basis of NEDD8 ubiquitin discrimination by the deNEDDylating enzyme NEDP1. EMBO J 2005;24(7):1341-51 (Pubitemid 40593055)
26. Sundqvist A, Liu G, Mirsaliotis A, et al. Regulation of nucleolar signaling to p53 through NEDDylation of L11. EMBO Rep 2009;10(10):1132-9
27. Dharmasiri S, Dharmasiri N, Hellman H, et al. The RUB/ Nedd8 conjugation pathway is required for early development in Arabidopsis. EMBO J 2003;22(8):1762-70 (Pubitemid 36460133)
28. Jones D, Candido EP. The NED-8 conjugating system in Caenorhabditis elegans is required for embryogenesis and terminal differentiation of the hypodermis. Dev Biol 2000;226(1):152-65
29. Kurz T, Ozlu N, Rudolf F, et al. The conserved protein DCN-1/Dcn1p is required for cullin neddylation in C. elegans and S. cerevisiae. Nature 2005;435(7046):1257-61 (Pubitemid 40943092)
30. Ou CY, Lin YF, Chen YJ, et al. Distinct protein degradation mechanisms mediated by Cul1 and Cul3 controlling Ci stability in Drosophila eye development. Genes Dev 2002;16(18):2403-14
31. Tateishi K, Omata M, Tanaka K, et al. The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol 2001;155(4):571-9 (Pubitemid 34289315)
32. Hori T, Osaka F, Chiba T, et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 1999;18(48):6829-34
33. Levine RL, Berlett BS, Moskovitz, et al. Methionine residues may protect proteins from critical oxidative damage. Mech Ageing Dev 1999;107(3):323-32 (Pubitemid 29210232)
34. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem 1999;274(51):36031-4
35. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253(5015):49-53 (Pubitemid 21917115)
36. Liu G, Xirodimas DP. NUB1 promotes cytoplasmic loclization of p53 through cooperation of the NEDD8 and ubiquitin pathways. Oncogene 2010;29(15):2252-61
37. Watson IR, Li BK, Roache O, et al. Chemotherapy induces NEDP1-mediated destabilization of MDM2. Oncogene 2010;29(2):297-304
38. Watson IR, Blanch A, Lin DC, et al. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 2006;281(45):34096-103 (Pubitemid 46036618)
39. Chairatvit K, Ngamkitidechakul C. Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Mol Cell Biochem 2007;306(1-2):163-9 (Pubitemid 350001828)
40. Salon C, Brambilla E, Brambilla C, et al. Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 2007;213(3):303-10 (Pubitemid 350074020)
41. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127(7):1323-34 (Pubitemid 44960417)
42. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445(7128):661-5 (Pubitemid 46232887)
43. Xue W, Zender L, Miething G, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445(7128):656-60 (Pubitemid 46232886)
44. Wilkinson KD, Smith SE, O'Connor L, et al. A specific inhibitor of the ubiquitin activating enzyme: synthesis and characterization of adenosyl-phosphoubiquitinol, a nonhydrolyzable ubiquitin adenylate analogue. Biochemistry 1990;29(32):7373-80 (Pubitemid 20251785)
45. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002;16(9):1713-24
46. Kauh J, Cohen R, Clarke JW, et al. Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin. J Clin Oncol 2009;27(15s):abstract 2562
47. Shah J, Jakubowiaket AJ, O'Connor O, et al. Phase 1 dose escalation study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. Am Soc Hematol, 2009;114 abstract 1854
48. Shah J, Jakubowiaket AJ, O'Connor O, et al. Phase 1 dose escalation study of MLN4924, a novel NAE inhibitor, in patients with multiple myeloma and non-Hodgkin lymphoma. Eur Hematol Assoc 2010;95 abstract 0394
49. Deshaies RJ. Drug discovery: fresh target for cancer therapy. Nature 2009;458(7239):709-10
50. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5(1):3-8 (Pubitemid 40321795)
51. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996;274(5289):948-53 (Pubitemid 26398409)
52. Aghajan M, Jonai N, Flick K, et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol 2010;28(7):738-42
53. Orlicky S, Tang X, Neduva V, et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 2010;28(7):733-7
54. Miranda-Carboni GA, Krumm SA, Yee K, et al. A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev 2008;22(22):3121-34
55. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327 (5973):1650-3
56. Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4 (DCAF1) in the nucleus. Cell 2010;140(4):477-90
57. Duda DM, Borg LA, Scott DC, et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 2008;134(6):995-1006
58. Jones J, Wu K, Yang Y, et al. A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins. J Proteome Res 2008;7(3):1274-87
59. Kurz T, Chou YC, Willems AR, et al. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. Mol Cell 2008;29(1):23-35
60. Pan ZQ, Kentsis A, Dias DC, et al. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 2004;23(11):1985-97 (Pubitemid 38496728)
61. Parry G, Estelle M. Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Semin Cell Dev Biol 2004;15(2):221-9 (Pubitemid 38251651)
62. Abida WM, Nikolaev A, Zhao W, et al. FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem 2007;282(3):1797-804 (Pubitemid 47076687)
63. Oved S, Mosesson Y, Zwang Y, et al. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem 2006;281(31):21640-51 (Pubitemid 44181867)
64. Lee MR, Lee D, Shin SK, et al. Inhibition of APP intracellular domain (AICD) transcriptional activity via covalent conjugation with Nedd8. Biochem Biophys Res Commun 2008;366(4):976-81
65. Stickle NH, Chung J, Klco JM, et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 2004;24(8):3251-61 (Pubitemid 38452070)
66. Gao F, Cheng J, Shi T, et al. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFkappaB-dependent transcription. Nat Cell Biol 2006;8(10):1171-7
67. Milhollen M, Narayanan U, Duffy J, et al. MLN4924, a potent and novel small molecule inhibitor of Nedd8 activating enzyme, induces DNA re-replication and apoptosis in cultured human tumor cells. Am Soc Hematol Annu Meet 2008;112 abstract 3621
68. Radhakrishnan SK, Lee CS, Young P, et al. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell 2010;38(1):17-28.